Key PointsQuestionWhat features prognosticate vascular risk and response to low-dose rivaroxaban and aspirin treatment among patients with symptomatic lower extremity peripheral artery disease? FindingsIn this secondary analysis of a randomized clinical trial, the risk of major vascular events was greater than 10% over 30 months for patients with previous peripheral revascularization, previous amputation, or Fontaine III or IV symptoms and patients with comorbidities of kidney dysfunction, heart failure, diabetes, or polyvascular disease. These patients at high risk had an estimated 4.2% absolute risk reduction for major vascular events when treated with combination rivaroxaban and aspirin vs aspirin alone. MeaningPer this analysis, patients with high-risk lower extremity peripheral artery disease limb presentations or comorbidities, who are not at high bleeding risk, should be considered for treatment with combination rivaroxaban and aspirin.
JAMA Cardiology – American Medical Association
Published: Jan 30, 2021